Compare IQIYI Inc - ADR (IQ) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Moderna, Inc. — how do they compare? IQIYI Inc - ADR trades at $1.26 (market cap $1.20B), while Moderna, Inc. trades at $59.72 (market cap $23.60B). The key difference: Moderna, Inc. is far larger — about 19.7× IQIYI Inc - ADR's market cap, and Moderna, Inc. is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| IQ | MRNA | |
|---|---|---|
Market Cap | $1.20B | $23.60B |
Sector | Media | Health |
52-Week High | $2.79 | $81.80 |
52-Week Low | $0.96 | $22.36 |
Enterprise Value | $2.76B | $19.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IQ stock trades at $1.235, up 3.78% today, with a bullish technical signal and mixed fundamentals. Revenue declined to $27.29B in 2025 with a net loss of $206.31M, but valuation ratios like P/S of 0.3 and P/B of 0.6 appear low. Recent news highlights AI initiatives and leadership changes, while analyst consensus is split with 50% buy ratings.
The outlook is cautious due to profitability challenges and projected revenue decline in 2026, but low valuations and AI-driven content strategy offer potential upside. Key risks include competitive pressures in streaming and regulatory uncertainty in China.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
